Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CerISMA

Financiado

Cerrado

Cerenkov Imaging for Surgical Margin Assessment

Cancer is not only a leading public health challenge in Europe, it is also a growing economic challenge. Over three million cases are currently diagnosed each year across the continent. Forecasts show that by 2020 almost half of t... ver más

30/06/2019

LIGHTPOINT

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LIGHTPOINT MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-06-30

PHC-12-2015: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LIGHTPOINT

2.35M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CLI The CLIO consortium Optimization of Cerenkov Luminescence I... 2M€ Cerrado

DPI2008-06691 TECNICAS PARA LA FUSION DE IMAGENES MR Y PET PARA LA LOCALIZ... 47K€ Cerrado

HELiCoiD HypErspectraL Imaging Cancer Detection 1M€ Cerrado

SENSITIVE Early Detection of cancer onset based on sensing field cance... 3M€ Cerrado

CONTRA CANCRUM Clinically Oriented Translational Cancer Multilevel Modellin... 5M€ Cerrado

FI2P4TUM Fluorescence intraoperative imaging platform for tumor margi... 163K€ Cerrado

Duración del proyecto: 43 meses Fecha Inicio: 2015-11-24
Fecha Fin: 2019-06-30

Líder del proyecto

LIGHTPOINT MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is not only a leading public health challenge in Europe, it is also a growing economic challenge. Over three million cases are currently diagnosed each year across the continent. Forecasts show that by 2020 almost half of the population will be diagnosed with the disease in their lifetime. The cost of cancer for the EU is €126 billion per year and rising. The health and economic implications of cancer therefore provide a compelling business opportunity for technologies that can improve health outcomes and reduce treatment costs. Surgery remains one of the primary treatments for cancer, yet surgeons lack the tools to identify accurately and remove cancer during an operation, resulting in costly re-operations and negative health ramifications. Lightpoint Medical has developed a molecular imaging camera (LightPath™) based on a breakthrough imaging modality, Cerenkov Luminescence Imaging (CLI). The technology can provide surgeons with real time intraoperative analysis of cancerous tissue to ensure the complete removal of cancer in a single operation. The device provides the potential for a dramatic reduction in costly re-operations and adjuvant therapies across a wide range of major cancer indications, proving not only an innovative solution for healthcare providers, but also a tool to substantially reduce cancer care costs. CerISMA is proposed as a multi-centre clinical trial to confirm the clinical efficacy of LightPath™ in a lead cancer indication and to evidence the health economic impact of the technology. The project is vital for the company’s growth, fundamentally underpinning the company’s ambitious sales and marketing strategy across strategic target territories in Europe and the US.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores